MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia

Oncogene

Volumn 30, Issue 31, 2011, Pages 3416-3428

  Gao, X N ^a   Lin, J ^a   Li, Y H ^a   Gao, L ^a   Wang, X R ^a   Wang, W ^a   Kang, H Y ^a   Yan, G T ^a   Wang, L L ^a   Yu, L ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

acute myeloid leukemia; c kit; DNA methylation; microRNAs; proto oncogenes; tumor suppressor genes

Indexed keywords

AZACITIDINE; LUCIFERASE; MICRORNA; MICRORNA 193A; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BIOASSAY; BLAST CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; EMBRYO; ENZYME ASSAY; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC TRANSFECTION; GRANULOCYTE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MALE; NONHUMAN; ONCOGENE C KIT; PRIORITY JOURNAL; PROMOTER REGION; RNA BINDING; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; AZACITIDINE; BONE MARROW CELLS; CELL LINE, TUMOR; CELLS, CULTURED; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; MONOCYTES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-KIT; YOUNG ADULT;

EID: 79961171626     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.62     Document Type: Article

References (45)

1. Ambros V. (2004). The functions of animal microRNAs. Nature 431: 350-355. (Pubitemid 39265675)
2. Agrawal S, Unterberg M, Koschmieder S, zur Stadt U, Brunnberg U, Verbeek W et al. (2007). DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res 67: 1370-1377.
3. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, Martin-Subero JI, Cordeu L, Garate L et al. (2009). Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 69: 4443-4453.
4. Bartel DP. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
5. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. (1985). Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103: 620-625.
6. Berg T, Guo Y, Abdelkarim M, Fliegauf M, Lubbert M. (2007). Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and-negative myeloid leukemia cell lines. Leuk Res 31: 497-506. (Pubitemid 46206089)
7. Blume-Jensen P, Hunter T. (2001). Oncogenic kinase signalling. Nature 411: 355-365. (Pubitemid 32467045)
8. Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A et al. (2006). Incidence and prognostic impact of c-kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20: 965-970. (Pubitemid 43797286)
9. Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC et al. (2008). Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13: 496-506. (Pubitemid 351763902)
10. Beghini A, Ripamonti CB, Cairoli R, Cazzaniga G, Colapietro P, Elice F et al. (2004). KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 89: 920-925. (Pubitemid 39049899)
11. Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB et al. (2006). Prognostic impact of c-kit mutations in core binding factor leukemias: an Italian retrospective study. Blood 107: 3463-3468.
12. Cui J, Fu H, Feng J, Zhu J, Tie Y, Xing R et al. (2007). The construction of miRNA expression library for human. Prog Biochem Biophys 34: 389-394. (Pubitemid 47138078)
13. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S et al. (2008). Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 68: 5049-5058.
14. Esquela-Kerscher A, Slack FJ. (2006). Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
15. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S et al. (2009). The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23: 1019-1028.
16. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F et al. (2005). MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 102: 18081-18086. (Pubitemid 41798505)
17. Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia-Manero G, Calin GA. (2008). MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 22: 1095-1105. (Pubitemid 351833775)
18. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. (2007). MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27: 91-105. (Pubitemid 46991392)
19. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T et al. (2009). MicroRNA 29b functions in acute myeloid leukemia. Blood 114: 5331-5341.
20. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E et al. (2009). MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113: 6411-6418.
21. Heidel F, Cortes J, Rucker FG, Aulitzky W, Letvak L, Kindler T et al. (2007). Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. Cancer 109: 907-914. (Pubitemid 46335678)
22. Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S et al. (2007). Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. Oncogene 26: 2445-2458. (Pubitemid 46597264)
23. Jiao B, Wu CF, Liang Y, Chen HM, Xiong SM, Chen B et al. (2009). AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia 23: 1598-1604.
24. Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B et al. (2004). Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 103: 3644-3654. (Pubitemid 38596277)
25. Kozaki KI, Imoto I, Mogi S, Omura K, Inazawa1 J. (2008). Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68: 2094-2105. (Pubitemid 351521781)
26. Lewis BP, Burge CB, Bartel DP. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20. (Pubitemid 40094598)
27. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D et al. (2008). A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 105: 13556-13561.
28. Li LC, Dahiya R. (2002). MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431. (Pubitemid 35414532)
29. Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J et al. (2008). miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res 36: 5391-5404.
30. Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. (2005). Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 23: 16-43. (Pubitemid 40105289)
31. Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N et al. (2009). Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancrea-tology 9: 293-301.
32. Larizza L, Magnani I, Beghini A. (2005). The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 46: 247-255. (Pubitemid 40185956)
33. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
34. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ et al. (2010). Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 17: 333-347.
35. Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P et al. (2008). MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1919-1928. (Pubitemid 351620112)
36. Osada H, Takahashi T. (2007). MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 28: 2-12. (Pubitemid 44942621)
37. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA et al. (2006). Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24: 3904-3911. (Pubitemid 46630738)
38. Reilly JT. (2003). Receptor tyrosine kinases in normal and malignant haematopoiesis. Blood Rev 17: 241-248. (Pubitemid 37356395)
39. Roman-Gomez J, Agirre X, Jimenez-Velasco A, Arqueros V, Vilas-Zornoza A, Rodriguez-Otero P et al. (2009). Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol 27: 1316-1322.
40. Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P et al. (2008). Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 22: 915-931. (Pubitemid 351709343)
41. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA et al. (2006). Specific activation of microRNA-127 with down-regulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435-443. (Pubitemid 43832188)
42. Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K et al. (2006). KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107: 1791-1799. (Pubitemid 43289355)
43. Tenen DG. (2003). Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3: 89-101. (Pubitemid 37328876)
44. Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX et al. (2005). AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 102: 1104-1109. (Pubitemid 40170733)
45. Youssef EM, Chen XQ, Higuchi E, Kondo Y, Garcia-Manero G, Lotan R et al. (2004). Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res 64: 2411-2417. (Pubitemid 38523894)